G1 Therapeutics is a biopharmaceutical company. Co. is developing two clinical stage programs. Co.'s primary compound trilaciclib is a therapy designed to improve outcomes for patients who are treated with chemotherapy. Trilaciclib helps protect hematopoietic stem and progenitor cells in bone marrow by inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in extensive stage small cell lung cancer patients. Also, Rintodestrant is an oral selective estrogen receptor degrader which Co. is developing as a monotherapy and in combination with a CDK4/6 inhibitor, Ibrance® (palbociclib), for the treatment of estrogen receptor-positive, HER2- breast cancer. The GTHX stock yearly return is shown above.
The yearly return on the GTHX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GTHX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|